Review Tuesday, September 7
All time in CET (EET = +1hr / BST = -1hr / EST = -6hr)
09:00 LSX Welcome
Josh Dance, SVP, LSX
09:10 How Nasdaq Nordics Markets are Driving Growth Capital for Nordic Life Sciences
Adam Kostyal, SVP, Nasdaq
Whilst a challenging year for many reasons,2020 felt like a step change for the Nordics, putting an already attractive region even more firmly on the map. A number of companies passed significant private and public fundraising, clinical and company development milestones, and these positives stories continued through into 2021.
While the life sciences and healthcare industry was put ever-more under focus, in the Nordics particularly the increased capital flow and interest from international investors, pharma and other key stakeholders interested in playing their part to continue to build the maturing Nordic ecosystem was clear to see. What is next for the sector as a whole and how are these companies planning to grow, develop and internationalise further?
Martin Welschof, CEO, BioInvent
Anders Martin-Löf, CFO, Oncopeptides
Renee Aguiar-Lucander, CEO, Calliditas Therapeutics
Moderator: Josh Dance, SVP, LSX
While challenges, opportunities and focus areas for investment are often discussed at length, what does analysis of key wider industry trends tell us about the true dynamics of European life sciences investment, and how it’s changing? Leading Nordic and European investors discuss what learnings can investors and companies alike take from key investment metrics.
Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures
Søren Moller, Managing Partner, Novo Seeds
Ingrid Teigland Akay, Managing Partner, Hadean Ventures
Moderator: Tony Proctor, Partner, Potter Clarkson
Strategic partnerships now play an increasing role in transforming the drug development process. A more structured, yet tailored approach combines acceleration with improved quality and compliance and allows for better insights and decision making. Effective partnerships are those that fit with both party’s needs, at the right times, and in the most suitable way, and this is key to the biotech’s success. This session presents a case study and lessons that can be learned from the effective collaboration along the drug development journey between a CRO and a biotech company.
Luke Gill, VP Clinical Development Services, TFS HealthScience
David Bejker, CEO, Affibody
While the wider European healthtech market is booming, the Nordics has become a frontrunner in digital innovation in healthcare. Nordic digital health and healthech innovation is gaining massive traction and attracting major investment. What has been key to this success and what is needed to secure the region as a globally competitive digital health innovation hub?
Anna-Karin Edstedt Bonamy, CEO, Doctrin
André Sode, CEO, Liva Healthcare
John Drakenberg Renander, CEO, Alex Therapeutics
Eric Teder, Country Manager Sweden, Doktor.se
Moderator: Jeremy McCrohan, Head of Investor Relations, Norway Healthtech
Jan Bart Hak, Head of Medical Device Department, ProPharma Group
Building a US presence at the right time is key for growing and internationalising European businesses. One Health is the integrative effort of multiple disciplines working locally, nationally, and globally to attain optimal health for people, animals, and the environment. Together, the three make up the One Health triad, and the health of each is inextricably connected to the others. Understanding and addressing the health issues created at this intersection is the foundation for the concept of One Health. The State of Iowa is well positioned, both, from a geographic as well as institutional and infrastructure position, to help businesses grow in this sector. This presentation will highlight:
Mark Laurenzo, Business Development Manager, Iowa Economic Development Authority
Life sciences is a global industry and cross-border deals are often critical for growth and internationalisation plans. Scientific, market, structural and cultural challenges are all key considerations in successful licencing, partnering or M&A deal across borders. Executives explore the optimal means of preparation of materials, readiness with relevant data and planning, as well as the pitfalls in these critical endeavours.
Søren Bregenholt, CEO, Alligator Bioscience
Magnus Corfitzen, CEO, Ascelia Pharma
Gunilla Oswald, CEO, BioArctic
Nathalie ter Wengel, European Lead Worldwide Business Development, Pfizer
Moderator: Greg Benning, Managing Director, Back Bay Life Science Advisors